Session I.- Breast Mucin and Associated Antigens in Diagnosis and Therapy.- Peptide Epitopes in Breast Cancer Mucins.- Does a Novel Form of the Breast Cancer Marker Protein, MUC1, Act as a Receptor Molecule that Modulates Signal Transduction?.- Cancer Metastasis Determined by Carbohydrate-Mediated Cell Adhesion.- Experimental Immunotherapy of Breast Cancer Using Alpha Interferon Conjugated to Monoclonal Antibody Mc5.- Circulating and Tissue Markers in the Longitudinal Management of Breast Cancer Patients.- Session II.- Engineering of Antibodies for Breast Cancer Therapy: Construction of Chimeric and Humanized Versions of the Murine Monoclonal Antibody BrE-3.- Humanization of an Anti-Mucin Antibody for Breast and Ovarian Cancer Therapy.- Towards an Immunotherapy for p185HER2 Overexpressing Tumors.- Session III.- Branching N-Linked Oligosaccharides in Breast Cancer.- Specificity of the IgG Response in Mice and Human Breast Cancer Patients Following Immunization Against Synthetic Sialyl-Tn, an Epitope with Possible Functional Significance in Metastasis.- Vaccination Against Breast Cancer - Studies in an Animal Model.- Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer.- The Simultaneous Expression of c-erbB-2 Oncoprotein and Laminin Receptor on Primary Breast Tumors has a Predicting Potential Analogous to that of the Lymph Node Status.- Multivariate Prognostic Model for Infiltrating Ductal Carcinoma of the Breast in the Axillary Node-Free Patient.- The Use of Monoclonal Antibody Immunoconjugates in Cancer Therapy.- Radioimmunolocalization of Breast Cancer Using BrE-3 Monoclonal Antibody.- Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study.- Overview of Radioimmunotherapy in Advanced Breast Cancer Using 1-131 Chimeric L6.- Contributors.

This volume focuses on the laboratory and clinical experience with targeting viral onco-antigens, while also reviewing the approaches to targeting self-cancer antigens in cancers of non-viral origin, where self-tolerance has been a challenge. It emphasizes the importance of selecting the right vaccine platform to induce a successful immune response against cancer antigens. In addition, the volume discusses the advances made with genetic vaccines, including recent advances with DNA vaccines and the rapid transition of mRNA vaccines from the laboratory to bedside. The new avenues opening up for cancer immunotherapy underline the importance of combinational approaches using cancer vaccines with costimulatory antibodies, which may dramatically improve cancer treatment. This book is intended for all translational researchers and clinicians who aspire to develop novel vaccination approaches for cancer patients with unmet clinical needs.

The aim of this open access book is to provide a unique, timely, critical and comprehensive compilation of more than 30 years of robust international experimental and clinical research related to the basic science and therapeutic application of water-filtered infrared-A (wIRA) and hyperthermia in oncology, psychiatry (depression), musculoskeletal disorders, dermatology, infectiology, and surgery. This is an internationally absolutely unique attempt which publication is timely and of great interest in medical as well as in natural sciences. The aim is to enhance communication and advance the use of heat therapy for patient benefit, and to generate an environment in which anyone with an interest in hyperthermia can discuss, collaborate, network, and share events and resources. Productive dialogue and discussion among scientists and practitioners on issues relating to hyperthermia therapy is essential, especially relating to thermal transmission by water-filtered infrared-A (wIRA). The specificity and advantage of this technology is its tolerance by tissue, and its penetration of up to 3 cm allows the delivery of high heat dosages that are relevant across multiple clinical indications. Currently, wIRA is being applied in Austria, Germany, Portugal, Switzerland, The Netherlands, UK and the USA. The authors' hope is that its use will increase in these countries, and also expand into others. This book will be an invaluable tool for oncologists, surgeons, dermatologists as well as physiotherapists.

A comprehensive collection of optimized methods for dissecting the mechanisms that control epidermal growth factors (EGF) and their regulators in both normal and pathological states. These readily reproducible techniques range from the study of purified EGF receptor to complex signaling and processing networks in intact cells, including a chapter on the clinical and pharmacological considerations of their use in cancer therapy. The protocols follow the successful Methods in Molecular Biology (TM) series format, each offering step-by-step laboratory instructions, an introduction outlining the principles behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls.

This volume provides detailed methods on the mechanisms of underlying cancer cell biology. Chapters guide readers through techniques for culturing cancer cell lines, xenografts, cryopreservation of tumor cells, analyzing the co-culture of breast cancer cells, protein secretion by ELISA, flow cytometry-based, multi-parametric immunofluorescence analysis, protein expression by western blot, analysis of surface protein levels, protein recycling by biotinylation assay, and proteomics analysis by liquid chromatography-mass spectrometry. Written in the format of the highly successful Methods in Molecular Biology series, each chapter includes an introduction to the topic, lists necessary materials and reagents, includes tips on troubleshooting and known pitfalls, and step-by-step, readily reproducible protocols. Authoritative and cutting-edge, Cancer Cell Biology: Methods and Protocols aims to provide a comprehensive set of tools for the analysis of cancer cell biology in the lab.

This book covers a wide range of topics that illustrate the various functions of autophagy in stem cells and offers insights on the mechanisms by which autophagy can regulate stem-cell self-renewal and facilitate specific differentiation programs. Stem cells are unique cells present in most multicellular animals and are essential for their survival. They have two unique properties: the ability to self-renew and the ability to differentiate into one or more cell types. These characteristics of stem cells have found immense therapeutic potential in regenerative medicine. Autophagy is a crucial membrane trafficking pathway that is essential for maintaining cellular homeostasis that involves sequestration of non-functional proteins, protein aggregates and damaged organelles in double-membraned vesicles called autophagosomes, which are subsequently targeted to the lysosome for degradation. The primary aim of this book is to provide knowledge of recent developments in our understanding of the role of autophagy in stem cells, including germline stem cells. Autophagy is considered a promising target for many diseases. Significant efforts are being developed to identify specific modulators of autophagy, which will aid in designing combinatorial therapeutic strategies that will allow significant improvements in regenerative medicine.

Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. The book brings together an impressive array of internationally distinguished investigators who are devoted to the study of cytokines and cancer.

Tumor necrosis factor (TNF)-? is a pleiotropic cytokine involved in a va- ety of physiological and pathological processes. After initial discovery of its ability to induce cell death and animal cachexia, it was soon realized that this cytokine played pivotal roles in the regulation of homeostasis and inflam- tory-immune responses. This led to an explosion of interest in basic and tra- lational research activities on the role of TNF in many diseases, such as cancer, septic shock, rheumatoid arthritis, and infectious diseases of the central n- vous system. Because of its potential therapeutic value, many academic and industrial research groups have worked to discover compounds that can block its activity. These studies have led to the approval of anti-TNF antibodies and soluble TNF receptors for the therapy of rheumatoid arthritis and Crohn's d- ease. TNF also can be an attractive anticancer agent capable of damaging tum- associated vessels and of inducing tumor necrosis in patients. The unique properties of TNF have led to its registration as a drug for locoregional tre- ment of sarcomas of the extremities, and stimulated many preclinical studies aimed at improving its therapeutic index for systemic use. Tumor Necrosis Factor: Methods and Protocols provides an overview of basic and translational research along with a series of practical procedures on TNF production, characterization, mutagenesis, detection in biological spe- mens, as well as several in vitro assays and animal models for studying the role of TNF in various diseases.

This book illustrates the significance of probiotics and prebiotics for the management of various types of cancers. The up-to-date chapters provide recent information about the effect of anticancer treatment approaches on gut microbiota, the correlation between ROS and synbiotics for effective cancer treatment, and the influence of synbiotics on inflammation and immune microenvironment for cancer treatment. It also describes the regulatory issues about synbiotics in the management of cancer. This book is an essential resource for scientists working in the field of cancer, pharmaceutical & clinical sciences, and cancer clinicians. This book is also very useful for undergraduate and postgraduate students of Pharmacy and Biotechnology and medical researchers, mainly working in microbiology, immunology, and cancer biology.

This sixth volume in the series Methods of Cancer Diagnosis, Therapy, and Prognosis discusses Ovarian Cancer, Renal Cancer, Urogenitary Cancer, Urinary Bladder Cancer, Cervical Uterine Cancer, Skin Cancer, Leukemia, Multiple Myeloma and Sarcoma. Both standard and emerging therapies for these cancers, written by expert oncologists/pathologists in this field, are included. This fully illustrated volume Identifies biomarkers based on genetic alterations for clear cell ovarian adenocarcinoma. Identifies subgroups of ovarian cancer by using differential gene expression. Includes the application of the power-Doppler imaging for distinguishing benign from malignant complex adrenal masses in ovarian cancer. Emphasizes the advantage of using cytoreduction surgery for diagnosing advanced ovarian cancer. Provides details on the treatment of kidney cancer with radiofrequency ablation, surgery, and chemotherapy. Explains the use of immunohistochemistry for diagnosing adenomatoid tumor of the adrenal gland. Discusses the chemotherapy of testicular cancer and related second primary tumors. Includes the diagnosis of urothelial bladder cancer with urine-based tumor markers. Explains the use of immunohistochemistry and MRI for diagnosing uterine cervical cancer and describes the staging of this cancer using PET alone or PET/CT. Describes the localization of malignant melanoma using FDG-PET/CT. Explains the use of prognostic receptors for nonmelanoma skin cancer. Details the treatment of multiple myeloma using immunotherapy, radiotherapy, and targeted radionuclide therapy. Presents diagnostic immunohistochemistry of synovial and Kaposi's sarcoma. The technological advances presented in this volume are expected to expedite new discoveries and their translation to clinical practice. The field of oncology will benefit the most from these advanced methods, as a combination of therapies and personalized medicine will improve early detection of thes

Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results."

Chemotherapy has made a dramatic difference to improved survival in patients with cancer. However, not all patients respond and some experience serious side effects.

"Pharmacogenetics: Making cancer treatment safer and more effective" is an up to date summary of the exciting new field of how genetic testing can tailor more effective prescription in oncology.

It is targeted at oncologists and professionals involved in the treatment of patients with cancer. It provides a core background in genetics and pharmacological principles before providing chapters from acknowledged experts in the field on genetic tests in specific cancer types, including breast, bowel and lung cancer. Clinical cases are used to illustrate the practical application of this knowledge.

Chapters on ethics, health economics and the industry aspects of pharmacogenetics set out the challenges and opportunities afforded by this new science.

Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of pemetrexed for the treatment of lung cancer and mesothelioma, and (ii) the demonstration that cell membrane-anchored folate receptors (FR) are exploitable for cancer and inflammatory disease management. FRs are not widely distributed in normal tissues, except on some luminal surfaces; however, they are accessible to systemically administered agents when expressed on many cancers as well as on activated macrophages involved in various inflammatory diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a wide range of payloads (including cytotoxic drugs) are currently being developed which exploit this property. The FR is also being utilized in immunotherapy approaches for the treatment of overexpressing cancers.

This thesis documents the development of a multifunctional nanoparticle system to enhance the chemotherapeutic efficiency of anti-cancer drugs, and contributes to research that helps decrease the side-effects in cancer patients while simultaneously increasing their survival rates. The work begins with an introduction to nanomedicine and cancer therapy, and contains a literature review on magnetic, gold, and core-shell nanoparticles. It also covers synthesis techniques, properties, various surface modifications, and the importance of magnetic and gold nanoparticles. The author dedicates a chapter to characterization techniques, experimental setup, and cell cultivation techniques for in-vitro studies. Further chapters describe the background, characterizations, and applications of multifunctional magnetite coated gold core-shell nanoparticles, and the doping of cobalt to magnetite and manganese to magnetite nanoparticles. The important highlight of this research was the control of the size, shape, composition, and surface chemistry of nanoparticles.

Representing the most relevant procedures and technologies aiding the advance of the field of HPV-mediated carcinogenesis of the cervix and other anatomical regions of squamocolumnar transition, such as the anorectum, penis, and oropharynx, Cervical Cancer: Methods and Protocols compiles a detailed collection of practical chapters. The first half of the book covers HPV types, pathogenesis of cervical cancer (CxCA), prevention, and novel potential drug targets, while the second half explores pathology, genomics, modeling of CxCA, and experimental therapeutic strategies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and vital, Cervical Cancer: Methods and Protocols serves as a valuable resource to both bench scientists and clinicians who step into the realm of high-risk HPVs and CxCA for the first time or those who wish to learn novel approaches or expand their toolbox for the study of CxCA.

There is no doubt that the advent of immunocytochemical techniques, by enhancing our ability to detect specific cell products or markers, has opened new avenues in the understanding of human diseases, and in our ability to perform better diagnosis in surgical pathology. The rapid development of this field has resulted in thousands of publications in the literature regarding immunocytochemistry in diagnostic pathology. This explosion of knowledge makes necessary publications summarizing what are the main markers available and how they can be used in the diagnosis of tumors. The need of a more organized and structured knowledge was evident during the workshop in Immunocytochemistry of Tumor Diagnosis that took place in the City of Detroit an October 1984. This book is the result of that workshop in which 22 chapters are focusing an the main subject of differential diagnosis of tumors. Jose Russo, M.D. Editor xiii ACKNOWLEDGEMENTS I wish to thank my many associates at the Michigan Cancer Foundation for their help in the preparation of this manuscript. I give thanks to Dr.

Psychosocial Resource Variables in Cancer Studies reviews the literature on selected psychosocial resource variables in cancer in order to raise and examine conceptual and methodological issues and to offer suggestions for future directions in the field. It provides investigators and clinicians with a systematic treatment of the state of the art in research on specific resource factors and provides a careful consideration of more generic methodological and statistical issues in this research context.Editors Curbow and Somerfield define resources as aspects of a person or environment that are brought to bear on the maintenance or restoration of adaptation under taxing conditions. They hope Psychosocial Resource Variables in Cancer Studies is just the beginning of an ongoing discussion within the field of psychosocial oncology on the nature and use of resource variables. The book's topics are crucial since researchers appear to be committed to using resource variables to explain outcomes. Also, resource variables are increasingly considered as explanatory concepts in quality-of-life research.Psychosocial Resource Variables in Cancer Studies offers critical reviews of the major resource variables investigated in contemporary psychosocial oncology research. It provides timely information on vital issues in this research, emphasizing studies of the influence of personal and social resources on adaptation to cancer. Chapters cover topics such as: the use of resource variables in the explanation of individual differences in adaptation to cancer and cancer treatment theories, measures, and methodological issues in the use of perceived control the use of the transactional model of coping to examine issues surrounding coping and the management of cancer demands religion and spirituality as resources in coping with cancer social support in adaptation to cancer and survival the clinical usefulness of research on psychosocial resources major measures of psychological functioning in psychosocial oncology research statistical and analytical issues in the use of resource variables roles of qualitative and quantitative approaches in exploring resource variablesThe editors begin with an overview of the oncology field and offer comments on issues that can be generalized to all psychosocial resource variables. Next is a presentation of a series of review papers on selected resource variables, including perceived control, coping, religion and spirituality, and social support, followed by a discussion of the clinical utility of research on these resource variables. The book concludes with a discussion of important cross-cutting methodological issues, including the selection of psychological functioning outcome measures, the statistical analysis of resource variables, and quantitative versus qualitative approaches.Psychosocial Reource Variables in Cancer is a valuable reference and guide for health psychologists, clinical health psychologists, clinical social workers in oncology, medical sociologists, medical anthropologists, and oncology nurses. It may also serve as important reading material for courses in health psychology, physiological factors in health and illness, personality and diseases, and stress and coping.

In recent years, increasing evidence has suggested that abnormal activation of signaling pathways is a critical event in cancer pathogenesis. In particular, activation of these pathways can lead to inappropriate cellular survival, proliferation, pluripotency, invasion, metastasis, and angiogenesis. Thus, understanding the mechanisms by which signaling pathways become subverted in a cancer cell can provide insight into critical events in cancer pathogenesis. Furthermore, as our ability to target specific molecular interactions advances, we now have the ability to design small molecules, protein therapeutics, and other forms of targeted therapies. By focusing on the specific molecular abnormalities in a cancer cell, these agents hold the potential to be much more effective and much less toxic than current cytotoxic therapies.

In recent years, serine proteases and matrix metalloproteinases (MMPs) have gained considerable attention in tumor biology. For most of these proteases, their expression is a reliable indication of ongoing tissue remodeling. This book provides a comprehensive evaluation of the mechanisms of action of proteases and their inhibitors in tumor biology. The first part provides the reader with a selective overview of the molecular biology of serine proteases, MMPs and their physiological inhibitors. The most important proteases and their physiological as well as synthetic inhibitors are evaluated in the most relevant models of experimental and human cancer. The clinical aspects are also taken into account.
This volume offers an update on this challenging aspect of cancer treatment, its interest bias, and possible clinical implication.

This book focuses on histone mutations, especially those mutations closely related to cancer. Genetic mutations and epigenetic alterations contribute to the development of a variety of cancers: recent genetic studies have identified e.g. H3K27M and H3G34R/V mutation in over 75% of DIPG cases, H3.3K36M mutation in more than 90% of chondroblastoma cases, and H3G34W/L mutation in over 90% of giant cell tumors of bone. Given the high incidence and tumorigenesis effects of histone H3 mutations, they are also referred to as oncohistones. This book highlights the advances made in the area over the past 10 years, and offers a state-of-the-art summary of epigenetic alternation, gene expression, protein structure, drug discovery, immunotherapy, and mouse modeling of histone H3 mutations in various tumors. Chiefly intended to provide researchers and graduate students with an overall picture of these mutations, it will also be of interest to researchers in basic oncology, clinical oncology, and epigenetics, as well as academics and clinical oncology practitioners.

The book provides a comprehensive overview of the current state, and the new concepts for the future directions of modern cancer therapy. Bringing together all the relevant aspects from basic and applied science, and the clinical experiences of this new direction in medicine, it is an up-to-date summary of the activities in the field and will be the basis for evaluating future progress in this area.

Rapid progress has been made in our understanding of the molecular mechanisms of cell growth and oncogenesis during the past decade. This book comprises recent results on the regulation of cell growth in normal and neoplastic tissues by growth factors including hormones, and by the activation and inactivation of oncogenes and tumor suppressor genes, respectively. Special attention has been given to the presentation of the frequently neglected close correlation between changes in signal transduction and metabolism pathways during oncogenesis.

This book describes all human leukemia-lymphoma cell lines that have been established and that grow continuously under standardised in vitro conditions. These lines are derived from cells belonging to all the major hematopoietic cell lineages, i.e. B- and T-lymphocytes, natural killer cells, granulocytic cells and megakaryocytic cells. The clinical data, the culture conditions and the major phenotypic features of the cell lines are described with citations. This book is the first book describing human leukemia-lymphoma cell lines and will be of interest to scientists involved in the areas of hematology, oncology, immunology, molecular biology and cytogenetics. Cancer Cell Lines, Volumes 1-3: These 3 volumes provide a comprehensive text on the culture of established cell lines from every type of human cancer. The volumes provide a basic manual and reference resource for every cancer research scientist using human cancer cells.